Skip to Main Content

Author Details

Alison F Munro
Institute of Genetics and Cancer, University of Edinburgh, Western General Hospital
2004
35
20
PMIDPaper TitleJournal TitlePublished Year
37450566Distinct neuroinflammatory signatures exist across genetic and sporadic amyotrophic lateral sclerosis cohorts.Brain2023
38079440A cautionary note on the use of N-acetylcysteine as a reactive oxygen species antagonist to assess copper mediated cell death.PLoS One2023
34856074Pathway profiling of a novel SRC inhibitor, AZD0424, in combination with MEK inhibitors for cancer treatment.Mol Oncol2022
35696676Multiparametric High-Content Cell Painting Identifies Copper Ionophores as Selective Modulators of Esophageal Cancer Phenotypes.ACS Chem Biol2022
34417202A Conformation Selective Mode of Inhibiting SRC Improves Drug Efficacy and Tolerability.Cancer Res2021
32616651The autophagy protein Ambra1 regulates gene expression by supporting novel transcriptional complexes.J Biol Chem2020
31757681High content phenotypic screening identifies serotonin receptor modulators with selective activity upon breast cancer cell cycle and cytokine signaling pathways.Bioorg Med Chem2020
31992186Unlocking the transcriptomic potential of formalin-fixed paraffin embedded clinical tissues: comparison of gene expression profiling approaches.BMC Bioinformatics2020
29131211Pharmaco-genomic investigations of organo-iridium anticancer complexes reveal novel mechanism of action.Metallomics2018
27115835Rapid Discovery and Structure-Activity Relationships of Pyrazolopyrimidines That Potently Suppress Breast Cancer Cell Growth via SRC Kinase Inhibition with Exceptional Selectivity over ABL Kinase.J Med Chem2016
25897160Predicting Anthracycline Benefit: TOP2A and CEP17-Not Only but Also.J Clin Oncol2015
26372731A four gene signature predicts benefit from anthracyclines: evidence from the BR9601 and MA.5 clinical trials.Oncotarget2015
26261265FLT1 signaling in metastasis-associated macrophages activates an inflammatory signature that promotes breast cancer metastasis.J Exp Med2015
26162681Potent organo-osmium compound shifts metabolism in epithelial ovarian cancer cells.Proc Natl Acad Sci U S A2015
23570501Is TIMP-1 immunoreactivity alone or in combination with other markers a predictor of benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial?Breast Cancer Res2013
23483540Prognosis of early breast cancer by immunohistochemistry defined intrinsic sub-types in patients treated with adjuvant chemotherapy in the NEAT/BR9601 trial.Int J Cancer2013
21390497The p160 ER co-regulators predict outcome in ER negative breast cancer.Breast Cancer Res Treat2012
22976805GSK3β and cyclin D1 expression predicts outcome in early breast cancer patients.Breast Cancer Res Treat2012
23047592Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer: results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trials.Br J Cancer2012
22644297Chromosome instability and benefit from adjuvant anthracyclines in breast cancer.Br J Cancer2012
22042366Chromosome 17 centromere (CEP17) duplication as a predictor of anthracycline response: evidence from the NCIC Clinical Trials Group (NCIC CTG) MA.5 Trial.Breast Cancer Res Treat2012
21796367Co-expression of SNAIL and TWIST determines prognosis in estrogen receptor-positive early breast cancer patients.Breast Cancer Res Treat2012
21638049In situ detection of HER2:HER2 and HER2:HER3 protein-protein interactions demonstrates prognostic significance in early breast cancer.Breast Cancer Res Treat2012
21917518HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data.Lancet Oncol2011
20079691Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601).Lancet Oncol2010
20615243Mammostrat as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapy.Breast Cancer Res2010
20676126Targeting anthracyclines in early breast cancer: new candidate predictive biomarkers emerge.Oncogene2010
19207951Membranous and cytoplasmic staining of Ki67 is associated with HER2 and ER status in invasive breast carcinoma.Histopathology2009
18768436Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial.J Clin Oncol2008
20477393Type I receptor tyrosine kinases as predictive or prognostic markers in early breast cancer.Biomark Med2008
17299391PTK (protein tyrosine kinase)-6 and HER2 and 4, but not HER1 and 3 predict long-term survival in breast carcinomas.Br J Cancer2007
16397033The role of HER1-HER4 and EGFRvIII in hormone-refractory prostate cancer.Clin Cancer Res2006
16722926Observer variation in immunohistochemical analysis of protein expression, time for a change?Histopathology2006
15685688Type I receptor tyrosine kinases are associated with hormone escape in prostate cancer.J Pathol2005
14687789HER2 and COX2 expression in human prostate cancer.Eur J Cancer2004
  • 1 - 35 of 35

Recommended Authors

Martin Sj??str??m
University of California-San Francisco
Career Start Year 2013
Number of shared co-authors 1
Tammy Piper
University of Edinburgh
Career Start Year 2012
Number of shared co-authors 14
Hans Kristian Moen Vollan
F Hoffmann-La Roche Ltd
Career Start Year 2010
Number of shared co-authors 3
Carmen Criscitiello
University of Milano
Career Start Year 2008
Number of shared co-authors 2
Samuel Leung
University of British Columbia
Career Start Year 2007
Number of shared co-authors 6
Catherine M Kelly
Mater Misericordiae University Hospital
Career Start Year 2006
Number of shared co-authors 4
Caterina Marchi??
University of Turin, Candiolo Cancer Institute, FPO-IRCCS
Career Start Year 2005
Number of shared co-authors 2
Christina Yau
University of California San Francisco
Career Start Year 2005
Number of shared co-authors 3
Aditya Bardia
Massachusetts General Hospital Cancer Center
Career Start Year 2004
Number of shared co-authors 1
David W Cescon
Princess Margaret Cancer Centre
Career Start Year 2003
Number of shared co-authors 5
Matthew P Goetz
Mayo Clinic
Career Start Year 2002
Number of shared co-authors 6
Siddhartha Deb
Olivia Newton-John Cancer Research Institute
Career Start Year 2002
Number of shared co-authors 1
Philippe L Bedard
Princess Margaret Cancer Centre, University Health Network
Career Start Year 2002
Number of shared co-authors 6
Darran P O'Connor
UCD Conway Institute, University College Dublin
Career Start Year 2001
Number of shared co-authors 5
Ingrid A Mayer
Vanderbilt University Medical Center
Career Start Year 2000
Number of shared co-authors 4
Massimo Cristofanilli
Weill Cornell School of Medicine
Career Start Year 1998
Number of shared co-authors 2
Ingrid Hedenfalk
Lund University and Skane University Hospital
Career Start Year 1997
Number of shared co-authors 4
Eleni Andreopoulou
New York Presbyterian Hospital
Career Start Year 1997
Number of shared co-authors 1
William M Gallagher
All-Island Cancer Research Institute, UCD Conway Institute, University College Dublin
Career Start Year 1996
Number of shared co-authors 6
Giuseppe Curigliano
University of Milan
Career Start Year 1996
Number of shared co-authors 3
Naoto T Ueno
Cancer Research Center of Hawaii: University of Hawai'i Cancer Center.
Career Start Year 1995
Number of shared co-authors 2
Rosemary L Balleine
Westmead Institute for Medical Research, The University of Sydney
Career Start Year 1993
Number of shared co-authors 4
Paul N Span
Radboud University Medical Center
Career Start Year 1993
Number of shared co-authors 4
Joan Albanell
Hospital del Mar Research Institute
Career Start Year 1990
Number of shared co-authors 1
Ben Ho Park
Vanderbilt University Medical Center
Career Start Year 1990
Number of shared co-authors 1
Funda Meric-Bernstam
University of Texas MD Anderson Cancer Center
Career Start Year 1990
Number of shared co-authors 3
John W M Martens
Erasmus Medical Center (MC) Cancer Institute
Career Start Year 1989
Number of shared co-authors 10
Gottfried E Konecny
David Geffen School of Medicine at University of California Los Angeles
Career Start Year 1984
Number of shared co-authors 2
Laura J Van't Veer
University of California San Francisco
Career Start Year 1984
Number of shared co-authors 8
Dennis J Slamon
David Geffen School of Medicine at university of california los angeles
Career Start Year 1973
Number of shared co-authors 3

Collaborators

John M S Bartlett
University of Edinburgh
Co-authored papers 23
Chris Twelves
Leeds Teaching Hospitals NHS Trust, University of Leeds
Co-authored papers 11
Melanie Spears
Ontario Institute for Cancer Research
Co-authored papers 4
Lois Shepherd
Queens University
Co-authored papers 4
Janet A Dunn
Warwick Clinical Trials Unit, University of Warwick
Co-authored papers 4
Kathleen I Pritchard
UCL Great Ormond Street Institute of Child Health, University College London
Co-authored papers 4
Carlos Caldas
Cancer Research UK Cambridge Institute, University of Cambridge
Co-authored papers 4
Daniel Rea
Institute of Cancer and Genomic Sciences, The University of Birmingham
Co-authored papers 3
Paul D P Pharoah
Center for Cancer Genetic Epidemiology, University of Cambridge
Co-authored papers 3
Mary Anne Quintayo
Ontario Institute of Cancer Research, MaRS Institute
Co-authored papers 2
Mark N Levine
Juravinski Hospital and Cancer Center
Co-authored papers 2
Fatima Cardoso
Champalimaud Clinical Center/Champalimaud Foundation
Co-authored papers 2
Anne R Bresnick
Albert Einstein College of Medicine
Co-authored papers 1
Lea Harrington
Institute for Research in Immunology and Cancer, Universite de Montreal
Co-authored papers 1
Mathew J Garnett
Wellcome Sanger Institute
Co-authored papers 1
Lisa A Carey
Co-authored papers 1
Susan G Hilsenbeck
Co-authored papers 1
Ultan McDermott
Wellcome Sanger Institute
Co-authored papers 1
Cornelis J H van de Velde
Leiden University Medical Center: Leids Universitair Medisch Centrum.
Co-authored papers 1
Jonine D Figueroa
The Usher Institute, The University of Edinburgh
Co-authored papers 1
Fouad Yousif
Ontario Institute for Cancer Research
Co-authored papers 1
Karen J Taylor
University of Edinburgh
Co-authored papers 1
Paul C Boutros
University of California los angeles
Co-authored papers 1
Lee Murphy
Edinburgh Clinical Research Facility, University of Edinburgh
Co-authored papers 1
Christos Sotiriou
Co-authored papers 1
Nicola Lyttle
Ontario Institute for Cancer Research, University Avenue
Co-authored papers 1
Elizabeth Mallon
Queen Elizabeth University Hospital
Co-authored papers 1
Brian Z Ring
Co-authored papers 1
Miki Tanioka
Co-authored papers 1
Carrie A Cunningham
Massachusetts General Hospital
Co-authored papers 1
Release 1.2